AGIO
NASDAQ · Biotechnology
Agios Pharmaceuticals Inc
$34.16
+1.08 (+3.26%)
Financial Highlights (FY 2026)
Revenue
62.55M
Net Income
-477,880,741
Gross Margin
88.3%
Profit Margin
-764.0%
Rev Growth
+56.0%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 88.3% | 88.3% | 41.3% | 41.3% |
| Operating Margin | -873.9% | -786.5% | -6.6% | -5.9% |
| Profit Margin | -764.0% | -725.8% | -5.7% | -6.3% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 62.55M | 40.10M | 198.27M | 200.72M |
| Gross Profit | 55.21M | 35.40M | 81.91M | 82.92M |
| Operating Income | -546,610,386 | -315,412,802 | -13,033,249 | -11,761,210 |
| Net Income | -477,880,741 | -275,753,457 | -11,344,752 | -12,565,080 |
| Gross Margin | 88.3% | 88.3% | 41.3% | 41.3% |
| Operating Margin | -873.9% | -786.5% | -6.6% | -5.9% |
| Profit Margin | -764.0% | -725.8% | -5.7% | -6.3% |
| Rev Growth | +56.0% | +56.0% | -2.9% | -8.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 267.01M | 273.20M |
| Total Equity | — | — | 1.12B | 1.12B |
| D/E Ratio | — | — | 0.24 | 0.24 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -540,592,353 | -329,270,202 | -15,767,673 | -13,652,238 |
| Free Cash Flow | — | — | -7,306,109 | -10,881,640 |